Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation
US7527972B2 · kind B2 · utility
0Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 16, 2006 |
| Grant date | May 5, 2009 |
| Priority date | — |
| Expiry date | Nov 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.